Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease
Open accessAbstract
The recently developed ultrasensitive bio-barcode assay was used to measure the concentration of amyloid-beta-derived diffusible ligands (ADDLs), a potential soluble pathogenic Alzheimer's disease (AD) marker, in the cerebrospinal fluid (CSF) of 30 individuals. ADDL concentrations for the subjects diagnosed with AD were consistently higher than the levels in the CSF taken from nondemented age-matched controls. Studies of ADDLs or for any other potential pathogenic AD markers in CSF have not been possible because of their low concentration in CSF (<1 pM). This study is a step toward a diagnostic tool, based on soluble pathogenic markers for the debilitating disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanotechnology-based immunoassays have established an Alzheimer's disease-dependent accumulation of oligomers in human cerebrospinal fluid.
“These assays, which can be many orders of magnitude more sensitive than ELISAs, have established an AD-dependent accumulation of oligomers in human CSF (Fukumoto et al., 2010; Gao et al., 2010; Georganopoulou et al., 2005; Haes et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Georganopoulou et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works
Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins
Nam, J., Thaxton, C. S., & Mirkin, C. A. (2003) · Science · doi:10.1126/science.1088755 · Cited by 2,391 · see citing works
Self-citationScanometric DNA array detection with nanoparticle probes.
Taton, T. A., Mirkin, C., & Letsinger, R. L. (2000) · Science · doi:10.1126/science.289.5485.1757 · Cited by 2,057 · see citing works
Self-citationNanoparticle-Based Bio-Barcodes for the Ultrasensitive Detection of Proteins*
Nam, J., Thaxton, C. S., & Mirkin, C. A. (2020) · Spherical Nucleic Acids · doi:10.1201/9781003056713-94 · Cited by 2,038 · see citing works
Self-citationPractice parameter: Management of dementia (an evidence-based review) [RETIRED]
Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,703 · see citing works
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · see citing works
What Controls the Melting Properties of DNA-Linked Gold Nanoparticle Assemblies?
Jin, R. M., Wu, G., Li, Z., Mirkin, C. A., & Schatz, G. C. (2003) · Journal of the American Chemical Society · doi:10.1021/ja021096v · Cited by 1,359 · see citing works
Self-citationPatterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328 · see citing works
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works
Self-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981 · see citing works
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works
Bio-Bar-Code-Based DNA Detection with PCR-like Sensitivity
Nam, J., Stoeva, S. I., & Mirkin, C. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049384+ · Cited by 744 · see citing works
Self-citationImproved discrimination of AD patients using β-amyloid <sub>(1-42)</sub> and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works
A Localized Surface Plasmon Resonance Biosensor: First Steps toward an Assay for Alzheimer's Disease
Haes, A. J., Hall, W. P., Chang, L., Klein, W. L., & Duyne, R. P. V. (2004) · Nano Letters · doi:10.1021/nl049670j · Cited by 708 · see citing works
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works
Self-Assembly of Aβ <sub>1</sub> <sub>-</sub> <sub>42</sub> into Globular Neurotoxins
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522 · see citing works
Self-citationEvolution of neuronal changes in the course of Alzheimer’s disease
Braak, H., & Braak, E. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_11 · Cited by 482 · see citing works
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works
Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349 · see citing works
Self-citationThe Molecular and Genetic Basis of Neurological Disease
Trojanowski, J. Q. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00013 · Cited by 341 · see citing works
Mirra, S. S. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00058-4 · Cited by 236 · see citing works
Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works
Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 167 · see citing works
Alzheimer's disease: treatments in discovery and development
Citron, M. (2002) · Nature Neuroscience · doi:10.1038/nn940 · Cited by 164 · see citing works
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
Galasko, D. R., Clark, C., Chang, L., Miller, B. L., Green, R. C., Motter, R. N., & Seubert, P. A. (1997) · Neurology · doi:10.1212/wnl.48.3.632 · Cited by 153 · see citing works
Self-citationCSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works
Chang, L., Bakhos, L., Wang, Z., Venton, D. L., & Klein, W. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:305 · Cited by 79 · see citing works
Self-citationBall, M. J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00052-3 · Cited by 34 · see citing works
Molecular imaging: Bridging the gap between neuroradiology and neurohistology.
Heckl, S., Pipkorn, R., Nägele, T., et al. (2004) · PubMed · doi:10.14670/hh-19.651 · Cited by 28 · see citing works
Spectral analysis of EEG coherence in Alzheimer s disease
Parra, M. A., Calderon, P. L., Llibre‐Rodriguez, J. J., & Gutiérrez, J. V. (2004) · Revista de Neurología · doi:10.33588/rn.3805.2003535 · Cited by 11 · see citing works
Accuracy of CT scan measurements of the medial temporal lobe in routine dementia diagnostics
Øksengaard, A. R., Haakonsen, M., Dullerud, R., Engedal, K., & Laake, K. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.823 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [3]Phelps, C., Khachaturian, Z. & Trojanowski, J. Q. (1997) Neurobiol. Aging 18**,** S1-S2.9330978 [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurobiol.%20Aging&volume=18&publication_year=1997&pages=S1&)]
- [6]Calderón, G. P. L., Parra, R. M. A., Llibre, R. J. J. & Gutiérrez, J. V. (2004) Rev. Neurol. 38**,** 422-427. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/15029518/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Rev.%20Neurol.&volume=38&publication_year=2004&pages=422&pmid=15029518&)]
- [27]Haes, A. J., Hall, L., Chang, W. P., Klein, W. L. & Van Duyne, R. P. (2004) Nano Lett. 4**,** 1029-1034. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nano%20Lett.&volume=4&publication_year=2004&pages=1029&)]
Cited by
Sorted by citations
Nanostructures in Biodiagnostics
Rosi, N. L., & Mirkin, C. A. (2005) · Chemical Reviews · doi:10.1021/cr030067f · Cited by 4,603 · see citing works
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · see citing works
Self-citationDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · see citing works
Self-citationThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works
Self-citationStructural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783 · see citing works
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · see citing works
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · see citing works
Self-citationIs Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621 · see citing works
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · see citing works
Self-citationAmyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · see citing works
Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03407.x · Cited by 559 · see citing works
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · see citing works
Self-citationKelley, S. O., Mirkin, C. A., Walt, D. R., Ismagilov, R. F., Toner, M., & Sargent, E. H. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.261 · Cited by 398 · see citing works
Self-citationFerreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · see citing works
Soluble Aβ oligomer production and toxicity
Larson, M. E., & Lesné, S. E. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07478.x · Cited by 356 · see citing works
Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases
Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007) · IUBMB Life · doi:10.1080/15216540701283882 · Cited by 335 · see citing works
Stress Biomarkers in Biological Fluids and Their Point-of-Use Detection
Steckl, A. J., & Ray, P. (2018) · ACS Sensors · doi:10.1021/acssensors.8b00726 · Cited by 319 · see citing works
Sensitive ELISA detection of amyloid‐β protofibrils in biological samples
Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292 · see citing works
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works
Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298 · see citing works
Self-citationHigh‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264 · see citing works
Deshpande, A., Kawai, H., Metherate, R., Glabe, C. G., & Busciglio, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5980-08.2009 · Cited by 232 · see citing works
Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease
Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., Ravetch, J., & Mayeux, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805902105 · Cited by 225 · see citing works
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · see citing works
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works
Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134 · see citing works
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129 · see citing works
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 113 · see citing works
Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105 · see citing works
Ngoepe, M., Choonara, Y., Tyagi, C., Tomar, L., Du Toit, L., Kumar, P., Ndesendo, V., & Pillay, V. (2013) · Sensors · doi:10.3390/s130607680 · Cited by 92 · see citing works
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64 · see citing works
Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.
Singh, A. V., Khare, M., Gade, W. N., & Zamboni, P. (2012) · Autoimmune Diseases · doi:10.1155/2012/160830 · Cited by 58 · see citing works
Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29 · see citing works
Self-citationAlzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27 · see citing works
- Authors
- Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-02-04
- Volume
- 102
- Issue
- 7
- Pages
- 2273-2276
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC548981
- OpenAlex
- W2118891894
- Cited by
- 835
- References
- 37
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 25 · 2023: 24 · 2022: 15 · 2021: 22 · 2020: 41 · 2019: 29 · 2018: 24 · 2017: 27 · 2016: 29 · 2015: 46 · 2014: 44 · 2013: 56 · 2012: 55
- FWCI
- 39.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation (0118025)
- U.S. Department of Defense
- National Institutes of Health (AG10161, AG11385, AG14449)
- National Institute on Aging (AG-11385, AG 10161, AG-14449, R37AG011385, P01AG014449, P30AG010161, R01AG011385)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, nanoparticle-based detection, ultrasensitive detection, early detection of Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Base Sequence, DNA, Humans, Ligands, Sensitivity and Specificity, Solubility, Biomarkers, Case-Control Studies, Polymerase Chain Reaction, Amyloid beta-Peptides, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
